A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Current treatments increase life expectancy but have limited impact on the progressive pulmonary vascular remodelling that drives PAH. Osteoprotegerin (OPG) is increased within serum and lesions of patients with idiopathic PAH and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Nadine D., Pickworth, Josephine A., West, Laura E., Dawson, Sarah, Carvalho, Joana A., Casbolt, Helen, Braithwaite, Adam T., Iremonger, James, Renshall, Lewis, Germaschewski, Volker, McCourt, Matthew, Bland-Ward, Philip, Kowash, Hager, Hameed, Abdul G., Rothman, Alexander M. K., Frid, Maria G., Roger Thompson, A. A., Evans, Holly R., Southwood, Mark, Morrell, Nicholas W., Crossman, David C., Whyte, Moira K. B., Stenmark, Kurt R., Newman, Christopher M., Kiely, David G., Francis, Sheila E., Lawrie, Allan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858314/
https://www.ncbi.nlm.nih.gov/pubmed/31729368
http://dx.doi.org/10.1038/s41467-019-13139-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858314/
https://www.ncbi.nlm.nih.gov/pubmed/31729368
http://dx.doi.org/10.1038/s41467-019-13139-9

Ejemplares similares